Chronic Obstructive Pulmonary Disease Treatment and Pharmacist-Led Medication Management

Drug Des Devel Ther. 2021 Jan 12:15:111-124. doi: 10.2147/DDDT.S286315. eCollection 2021.

Abstract

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death across the globe. Its repeated exacerbation will seriously worsen the quality of life, aggravate the patients' symptoms, and bring a heavy burden on the patients and the society. Understanding the current status of drug therapy and the role of pharmaceutical care is essential for the management of COPD. In addition to the drugs already on the market, recent clinical trials also show that emerging novel drugs for treating COPD are being developed to prevent the symptoms, reduce the frequency of acute exacerbation, and improve the quality of life. Recent progress in new drug research should lead to novel treatment options for COPD patients in future clinical practice. The pharmaceutical care has shown significantly favourable impacts on addressing drug-related problems, supporting its vital role in the management of COPD, especially when there are a wide range of therapeutic agents. This review not only provides an overview of current treatment strategies but also further underlines the importance of new drug development and pharmaceutical care for patients with COPD.

Keywords: chronic obstructive pulmonary disease; clinical trial; complications; drugs; pharmaceutical care.

Publication types

  • Review

MeSH terms

  • Bronchodilator Agents / therapeutic use*
  • Humans
  • Medication Therapy Management*
  • Pharmacists*
  • Pulmonary Disease, Chronic Obstructive / drug therapy*

Substances

  • Bronchodilator Agents

Grants and funding

This work was supported by the Zhejiang Provincial Natural Science Foundation of China (No. LYY19H280006), the National Natural Science Foundation of China (No. 81503129), the Zhejiang Provincial Science Technology Projects of Traditional Chinese Medicine (No. 2021ZB174), the Clinical Research Projects of Zhejiang Medical Association (No. 2019ZYC-A85).